Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting
May 18, 2022 07:00 ET
|
Passage Bio
Longer-term follow-up showed continued developmental improvement for both patients in assessments by study investigators and caregiversInterim safety data at 13 and seven months from patients in...
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
May 16, 2022 07:00 ET
|
Passage Bio
Dosed first patient in Cohort 2 and completed dosing of Cohort 3 in Imagine-1 clinical trial for GM1 gangliosidosis; interim safety and biomarker data for both cohorts expected in 2H22Dosed first...
Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022
May 09, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
UPDATE - Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
May 03, 2022 14:13 ET
|
Passage Bio
PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
May 02, 2022 16:01 ET
|
Passage Bio
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 22, 2022 16:01 ET
|
Passage Bio
PHILADELPHIA, April 22, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease
March 29, 2022 07:00 ET
|
Passage Bio
Preclinical studies conducted with University of Pennsylvania’s Gene Therapy Program demonstrate biologic effects of vector-optimized gene therapy PBKR03 for Krabbe diseasePBKR03 showed marked...
Passage Bio to Participate in Upcoming Investor Conferences
March 28, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, March 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway
March 15, 2022 07:00 ET
|
Passage Bio
Company to reduce workforce and prioritize research and development programs to reduce operating expensesContinued focus on execution of three ongoing clinical trials for GM1 gangliosidosis, Krabbe...
Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition
March 10, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...